Variant Bio

Brooklyn, United States Founded: 2018 • Age: 8 yrs
Personalized therapeutics are developed using genomic data for rare diseases.
Request Access

About Variant Bio

Variant Bio is a company based in Brooklyn (United States) founded in 2018 by Stephane Castel and Kaja Wasik.. Variant Bio has raised $127.74 million across 3 funding rounds from investors including Lux Capital. Variant Bio offers products and services including Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations. Variant Bio operates in a competitive market with competitors including Viome, Invitae, Color, Everlywell and Newtopia, among others.

  • Headquarter Brooklyn, United States
  • Founders Stephane Castel, Kaja Wasik
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $127.74 M (USD)

    in 3 rounds

  • Latest Funding Round
    $105 M (USD), Series B

    Nov 17, 2021

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Variant Bio

Variant Bio offers a comprehensive portfolio of products and services, including Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for analyzing human genes to identify therapy targets.

Services for generating genomic data to support drug development.

Programs for ethical partnerships in genomics and benefit sharing.

People of Variant Bio
Headcount 10-50
Employee Profiles 27
Board Members and Advisors 22
Employee Profiles
People
Oscar Sias
Discovery Research
People
Andrew Farnum
CEO
People
Yvette Latchman
Discovery Research
People
Holly Vance
Chief Operating Officer & Chief Legal Officer

Unlock access to complete

Board Members and Advisors
people
Josh Wolfe
Board Member
people
Bob More
Board Member
people
Stuart Nagae
Board Member
people
Karen Akinsanya
Scientific Advisor

Unlock access to complete

Funding Insights of Variant Bio

Variant Bio has successfully raised a total of $127.74M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $105 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series B — $105.0M
  • First Round

    (10 Oct 2019)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2021 Amount Series B - Variant Bio Valuation

investors

Aug, 2020 Amount Series A - Variant Bio Valuation

investors

Oct, 2019 Amount Series A - Variant Bio Valuation Lux Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Variant Bio

Variant Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Lux Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Seed and early-stage technology companies are funded by Lux Capital.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Variant Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Variant Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Variant Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Variant Bio

Variant Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viome, Invitae, Color, Everlywell and Newtopia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Machine learning-based bioinformatics solutions for health insights are provided.
domain founded_year HQ Location
Home-based genetic tests for detecting diseases are provided to individuals.
domain founded_year HQ Location
Cancer care is delivered through a virtual clinic by Color.
domain founded_year HQ Location
At-home health tests for biomarkers, nutrition, and hormone analysis.
domain founded_year HQ Location
Health management platform is provided for employers and insurers.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Variant Bio

Frequently Asked Questions about Variant Bio

When was Variant Bio founded?

Variant Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Variant Bio located?

Variant Bio is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.

Who is the current CEO of Variant Bio?

Andrew Farnum is the current CEO of Variant Bio.

Is Variant Bio a funded company?

Variant Bio is a funded company, having raised a total of $127.74M across 3 funding rounds to date. The company's 1st funding round was a Series A of $16.64M, raised on Oct 10, 2019.

What does Variant Bio do?

Variant Bio was founded in 2018 and is headquartered in Brooklyn, United States. The company operates in the biotechnology sector, focusing on genomics to address rare diseases. A platform is provided for detecting human genetic diversity, enabling the development of targeted treatment solutions. Services emphasize personalized therapeutics derived from genetic analysis to support therapeutic advancements in underserved medical areas.

Who are the top competitors of Variant Bio?

Variant Bio's top competitors include Viome, Newtopia and Invitae.

What products or services does Variant Bio offer?

Variant Bio offers Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations.

Who are Variant Bio's investors?

Variant Bio has 1 investor. Key investors include Lux Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available